Article
Multidisciplinary Sciences
Fanying Tang, Duo Xu, Shangqian Wang, Chen Khuan Wong, Alexander Martinez-Fundichely, Cindy J. Lee, Sandra Cohen, Jane Park, Corinne E. Hill, Kenneth Eng, Rohan Bareja, Teng Han, Eric Minwei Liu, Ann Palladino, Wei Di, Dong Gao, Wassim Abida, Shaham Beg, Loredana Puca, Maximiliano Meneses, Elisa de Stanchina, Michael F. Berger, Anuradha Gopalan, Lukas E. Dow, Juan Miguel Mosquera, Himisha Beltran, Cora N. Sternberg, Ping Chi, Howard Scher, Andrea Sboner, Yu Chen, Ekta Khurana
Summary: This study classified CRPC into different subtypes using ATAC-seq, RNA-seq, and DNA sequencing. The identified subtypes include AR-dependent, neuroendocrine, Wnt-dependent, and stem cell-like subtypes driven by AP-1 transcription factors. Transcriptomic signatures were used for patient classification, and SCL was found to be the second most common subtype of CRPC.
Article
Oncology
Bram De Laere, Alessio Crippa, Ashkan Mortezavi, Christophe Ghysel, Prabhakar Rajan, Martin Eklund, Alexander Wyatt, Luc Dirix, Piet Ost, Henrik Gronberg, Johan Lindberg
Summary: Circulating tumour DNA profiling can efficiently accelerate biomarker discovery in oncology trials. In metastatic castration-resistant prostate cancer, the complex genomic landscape with rare driver gene alterations complicates biomarker identification, requiring large sample sizes for evaluation. Grouping genomic alterations within the same cellular pathways may provide increased precision for biomarker discovery, highlighting the importance of comprehensive genomic profiling for prognosis and treatment outcomes.
Article
Multidisciplinary Sciences
Weijie Zhang, Adam M. Lee, Sampreeti Jena, Yingbo Huang, Yeung Ho, Kiel T. Tietz, Conor R. Miller, Mei-Chi Su, Joshua Mentzer, Alexander L. Ling, Yingming Li, Scott M. Dehm, R. Stephanie Huang
Summary: Prostate cancer (PC) is a common malignancy in US men and often develops into castration-resistant prostate cancer (CRPC), which is resistant to hormonal therapies. This study presents a computational framework to predict drug sensitivities of clinical CRPC tumors and identify potential treatment options. The method was applied to a CRPC patient cohort, resulting in the nomination of drugs currently undergoing clinical trials for CRPC. The method also identified a tetracycline derivative with higher efficacy in enzalutamide-resistant CRPC models. This computational framework shows promise in accelerating drug development for CRPC.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Vicenc Ruiz de Porras, Albert Font, Alvaro Aytes
Summary: Taxanes are currently the most active chemotherapy drugs used in the treatment of mCRPC, but resistance easily develops, limiting long-term survival. Platinum-based treatments, in addition to taxanes, are the limited therapeutic options for patients progressing to taxanes. Therefore, further research on the role of platinum-based chemotherapy in mCRPC and the identification of predictive biomarkers are urgently needed.
Editorial Material
Biochemistry & Molecular Biology
Jonathan B. Coulter, Hariharan Easwaran
Summary: A new study in PLOS Biology suggests that combined therapy targeting EZH2 and HDACs may enhance the sensitivity of castration-resistant prostate cancer to both epigenetic and standard therapies.
Article
Oncology
Zainab A. H. Alebady, Mahsa Azizyan, Sirintra Nakjang, Emma Lishman-Walker, Dhuha Al-Kharaif, Scott Walker, Hui Xian Choo, Rebecca Garnham, Emma Scott, Katya L. L. Johnson, Craig N. N. Robson, Kelly Coffey
Summary: This study uncovers the genes and cellular pathways regulated by methyltransferase KMT5A in prostate cancer, providing insight into its oncogenic properties and potential therapeutic targeting. The key regulator CDC20 is shown to be controlled by KMT5A through histone methylation and p53 inhibition. Clinical samples further support the correlation between KMT5A and CDC20 expression, suggesting their importance as therapeutic targets for prostate cancer.
Article
Oncology
Ze Wang, Xuzhi Yan, Peng Tang, Tang Tang, Yapeng Wang, Song Peng, Shuo Wang, Weihua Lan, Luofu Wang, Yao Zhang, Jun Zhang, Ke Li, Zehua Shu, Jing Xu, Jun Qin, Dianzheng Zhang, Jun Jiang, Qiuli Liu
Summary: This study demonstrated that cfDNA can be used for genetic profiling in prostate cancer, and our established panel of genetic mutations is capable of predicting high risk of early CRPC progression in mHSPC patients.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Bobby C. Liaw, Che-Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh
Summary: This study evaluated the feasibility and usefulness of blood-based biomarkers to identify platinum-sensitive mCRPC. Although some biomarkers were assessed, none were significantly associated with response to satraplatin.
Article
Oncology
Anita Csizmarik, David Keresztes, Nikolett Nagy, Thilo Bracht, Barbara Sitek, Kathrin Witzke, Martin Puhr, Ilona Tornyi, Jozsef Lazar, Laszlo Takacs, Gero Kramer, Sabina Sevcenco, Agnieszka Maj-Hes, Zsolt Juranyi, Boris Hadaschik, Peter Nyirady, Tibor Szarvas
Summary: The study identified ALCAM as an important factor in ENZA resistance and showed that serum levels of ALCAM can help differentiate resistant patients, which is crucial for optimizing future clinical decisions.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Wen Tao, Zi-Huan Luo, Ya-Di He, Bang-Yu Wang, Tao-Lin Xia, Wei-Ming Deng, Ling-Xiao Zhang, Xiu-Mei Tang, Zhan-Ao Meng, Xin Gao, Liao-Yuan Li
Summary: This study developed a plasma extracellular circRNA-based signature that can predict overall survival in mCRPC patients undergoing abiraterone therapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
I. Gusti Md Gde Surya C. Trapika, Xin Tracy Liu, Long Hoa Chung, Felcia Lai, Chanlu Xie, Yang Zhao, Shaohui Cui, Jinbiao Chen, Collin Tran, Qian Wang, Shubiao Zhang, Anthony S. Don, George Qian Li, Jane R. Hanrahan, Yanfei Qi
Summary: Prostate cancer is the second most prevalent malignancy worldwide, thus novel treatments are urgently needed. Research shows that erianin exhibits anti-tumor effects in both androgen-sensitive and castration-resistant prostate cancer cells through different mechanisms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Blossom Mak, Hui-Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate Mahon, Martin R. Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Andrew J. Hoy, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, David J. Waugh, Lisa M. Butler, Manish Kohli, Peter J. Meikle, Arun A. Azad, Lisa G. Horvath
Summary: This study assessed the association between circulating lipids, somatic genetic aberrations, and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The results revealed that certain genetic aberrations were associated with elevated circulating sphingolipids, and patients with both genetic and lipid abnormalities had worse prognosis. These findings may have implications for the selection of metabolic therapies.
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Review
Biochemistry & Molecular Biology
Doo Yong Chung, Jee Soo Ha, Kang Su Cho
Summary: The treatment goals for patients with non-metastatic castration-resistant prostate cancer are to delay metastasis, preserve quality of life, and increase overall survival. Second-generation androgen receptor inhibitors have shown substantial improvements in clinical trials, with high safety profile and ability to delay disease progression.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Xiaofan Pu, Chaolei Zhang, Guoping Ding, Hongpeng Gu, Yang Lv, Tao Shen, Tianshu Pang, Liping Cao, Shengnan Jia
Summary: This study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyang
Summary: This study demonstrates the significance of PD-1 in EBV-infected lymphoma cells. Silencing PD-1 enhances the tumor targeting effect of EBV-specific killer T cells on B lymphocytes and attenuates the immune escape effect.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Qiliang Peng, Jialong Tao, Yingjie Xu, Yi Shen, Yong Wang, Yang Jiao, Yiheng Mao, Yaqun Zhu, Yulong Liu, Ye Tian
Summary: This study investigates the potential role of lipid metabolism-associated genes (LMAGs) in neoadjuvant chemoradiotherapy (nCRT) and immunotherapy for rectal cancer. The results suggest that the SREBF2 gene is a highly predictive factor for nCRT in rectal cancer and is associated with favorable prognosis. SREBF2 is also closely associated with immune cell infiltration and immunotherapy-related genes.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Shiquan Li, Nan Zhang, Yongping Yang, Tongjun Liu
Summary: This study investigated the potential molecular mechanism of SPDEF in immune evasion of colorectal cancer (CRC) and found that it suppresses immune evasion by activating CCL28 through the modulation of M2 polarization of macrophages. These findings provide a new research direction and potential therapeutic target for immunotherapy in CRC.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Manas Sehgal, Soundharya Ramu, Joel Markus Vaz, Yogheshwer Raja Ganapathy, Srinath Muralidharan, Sankalpa Venkatraghavan, Mohit Kumar Jolly
Summary: This study investigates the relationship between gene expression patterns and phenotypic plasticity and heterogeneity in colorectal cancer (CRC). The results demonstrate the interconnectedness between different Consensus Molecular Subtypes (CMS) of CRC and specific phenotypes such as epithelial and mesenchymal characteristics. Additionally, the study reveals correlations between metabolic pathways and phenotypic scores, as well as between PD-L1 activity and mesenchymal phenotype. Single-cell RNA sequencing analysis further confirms the heterogeneity of different CMS subtypes. These findings have important implications for understanding CRC heterogeneity and developing targeted therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yutong Zou, Siyao Guo, Yan Liao, Weidong Chen, Ziyun Chen, Junkai Chen, Lili Wen, Xianbiao Xie
Summary: This study found that ceramide metabolism is associated with the progression and clinical outcome of osteosarcoma by analyzing data from osteosarcoma patients. The gene ST3GAL1 plays an important role in osteosarcoma, regulating the tumor immune microenvironment and affecting T cell function. It may become a new target for the treatment of osteosarcoma.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Chuanhui Chen, Mengzhi Wan, Xiong Peng, Qing Zhang, Yu Liu
Summary: This study examines the function and mechanism of the ceRNA network centered around GPR37 in LUAD. The findings show that high expression of GPR37 in LUAD tissue samples is associated with poor prognosis, and it may regulate the expression of downstream target genes by competitively binding to lncRNA DLEU1 and miR-4458.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Junping Li, Hong Hu, Jinping He, Yuling Hu, Manting Liu, Bihui Cao, Dongni Chen, Xiaodie Ye, Jian Zhang, Zhiru Zhang, Wen Long, Hui Lian, Deji Chen, Likun Chen, Lili Yang, Zhenfeng Zhang
Summary: Sequential administration of CDC7 inhibitor XL413 after carboplatin enhances the chemotherapeutic effect of carboplatin on ovarian cancer cells, possibly by inhibiting homologous recombination repair activity and increasing the accumulation of chemotherapy-induced DNA damage.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Madison Catalanotto, Joel Markus Vaz, Camille Abshire, Reneau Youngblood, Min Chu, Herbert Levine, Mohit Kumar Jolly, Ana -Maria Dragoi
Summary: The study demonstrates that loss of FLASH in cancer cells leads to a hybrid E/M phenotype with high epithelial scores, suggesting FLASH acts as a repressor of the epithelial phenotype. Additionally, FLASH expression is inversely correlated with the epithelial score and subsets of mesenchymal markers are distinctly up-regulated in FLASH, NPAT, or SLBP-depleted cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang
Summary: Adipocytes are derived from pluripotent mesenchymal stem cells and histone modifications play a key role in their differentiation. Recent studies have shown that cancer stem cells can differentiate into adipocytes, reducing the malignancy of cancer cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat
Summary: Cancer heterogeneity and drug resistance are major obstacles to effective cancer treatment, and epigenetic modifications play a pivotal role in these processes. This review explores essential epigenetic modifications, including DNA methylation, histone modifications, and chromatin remodeling, and discusses their complex contributions to cancer biology. However, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to fully exploit the potential of epigenetic modifications.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo C. A. da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis
Summary: The TIS and IFN-gamma signatures are predictive biomarkers for identifying NSCLC patients who could potentially benefit from immune checkpoint inhibitor therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Giovanni Marchi, Anna Rajavuori, Mai T. N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Summary: The study shows that ctDNA can adequately represent high-grade serous ovarian carcinoma (HGSC), and the mutations observed at relapse suggest personalized therapy options.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yuncang Yuan, Jiawei Fan, Dandan Liang, Shijie Wang, Xu Luo, Yongjie Zhu, Nan Liu, Tingxiu Xiang, Xudong Zhao
Summary: This study demonstrates that csGRP78-directed CAR-T cells can selectively kill pancreatic cancer cells, and the combination with chemotherapy enhances cytotoxicity.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Niyati Piplani, Tanusri Roy, Neha Saxena, Shamik Sen
Summary: The glycocalyx, a protective barrier surrounding cells, has been found to play a role in cancer cell proliferation, survival, and metastasis. However, its function in maintaining DNA/nuclear integrity during migration through dense matrices has not been explored. This study shows that the bulkiness of the glycocalyx is inversely associated with nuclear stresses, and highlights its mechanical role in shielding migration-associated stresses.
TRANSLATIONAL ONCOLOGY
(2024)